
Which patients with esophageal cancer should not be operated?

George Hanna PhD, FRCS Head of Division of Surgery Imperial College London

Decision to operate



Patient

Severe co-morbidity


Clear decision

Marginal fitness

Pre-op optimisation

Enhanced recovery


Personalised multi-modal pre-habilitation








PREPARE programme



Post-op complications (Clavien-Dindo)



Metastatic disease

No role for palliative oesophagectomy

- Distant organs metastasis
- Peritoneal disease
- Metastatic cervical, para-aortic lymph nodes

Yes regional LN: coeliac, along recurrent nerves

T4b disease

No advantage for incomplete resection

- Airways
- Aorta
- Invasion of recurrent laryngeal nerves

Yes T4a: pleura, diaphragm, pericardium, limited lung resection

M1, T4b disease

- No survival advantage for surgery
- Surgery compromises quality of life
- Superior options
 - Stents for dysphagia
 - Pain management
- Role for palliative oncological therapies

Early, T1a disease

Endoscopic resection


- Low incidence of LN involvement
- Can achieve complete resection
- No long term post-oesophagectomy symptoms
- Preserve quality of life

Upper oesophageal squamous cell carcinoma

- Superior outcomes of radical chemo-radiotherapy compared to surgery

Yes: salvage oesophagectomy in selected cases for small residual disease

Surgical strategy



Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review

Sheraz R Markar, Tom Wiggins, Melody Ni, Ewout W Steyerberg, J Jan B Van Lanschot, Mitsuru Sasako, George B Hanna

- 33 RCTs 7045 patients
- Investigated whether standarisation of surgical techniques reduces the variation in lymph node harvest, in-hospital mortality and loco-regional cancer recurrence

Quality of Surgery in RCTs


Results of RCTs depend on

- Credentialing surgeons before enrollment in study
- Standardisation of surgical techniques
- Monitoring of surgical performance during trial

Lancet oncology 2015

Local clearance


Recurrence after neo-adjuvant chemotherapy



Recurrence (47 vs. 16% - P<0.001)

Local clearance

Disease free survival after neo-adjuvant chemotherapy




CUSUM (risk adjusted cumulative sum)

Disease free survival (22 to 36 months; P=0.028)

Local clearance

after neo-adjuvant chemo radiotherapy



CUSUM (risk adjusted cumulative sum)

No lymph node threshold count

Neo-adjuvant chemo radiotherapy

Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy

Prognostic and Therapeutic Impact on Survival

A. Koen Talsma, MD,* Joel Shapiro, MD,* Caspar W. N. Looman, PhD,† Pieter van Hagen, MD,* Ewout W. Steyerberg, PhD,† Ate van der Gaast, MD, PhD,‡ Mark I. van Berge Henegouwen, MD, PhD,§ Bas P. L. Wijnhoven, MD, PhD,* and J. Jan B. van Lanschot, MD, PhD*; On behalf of CROSS Study Group

(Ann Surg 2014;260:786-793)

Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location

Boris Sepesi, MD, Henner E. Schmidt, MD, Michal Lada, MD, Arlene M. Correa, PhD, Garrett L. Walsh, MD, Reza J. Mehran, MD, David C. Rice, MD, Jack A. Roth, MD, Ara A. Vaporciyan, MD, Jaffer A. Ajani, MD, Thomas J. Watson, MD, Stephen G. Swisher, MD, Donald E. Low, MD, and Wayne L. Hofstetter, MD

(Ann Thorac Surg 2016;101:1075-81)


Lymphadenectomy along superior mediastinum

- Squamous cell carcinoma (38% +ve LN)
- Adenocarcinoma up to mid-oesophagus (36% +ve LN)

Mine et al Ann Surg Oncol 2014


- Enlarged lymph nodes in superior mediastinum
- N3 disease

LN size cannot be the basis for extent of surgery




Hanna et al. Histopathology 2013

ру N3




Significance of Microscopically Incomplete Resection Margin After Esophagectomy for Esophageal Cancer



(Ann Surg 2016;263:712-718)

Circumferential margin



Which patients with esophageal cancer should not be operated?

Patient

critical co-morbidities that cannot be optimised

Disease

M, T4b, T1a, SCC in superior mediastinum

Surgical strategy

cannot achieve local and regional clearance

Thank you